Outcomes study to assess statin residual risk reduction with Epanova in high CV risk patients with hypertriglyceridemia (STRENGTH)
Unique positioning: short tripeptide, exceptional copper stability, 50-year corpus, commercial cosmetic use integrated since the 1990s, broadest documented genomic modulation for a peptide
Sixth, peptide stability, solubility, and purity are useful laboratory characteristics, but they do not establish human safety, pharmacology, or clinical value
FEBS letters, 238(2), 343346
Of note, an enormous number of the interactions between the genes involved obscure the final outcome
ABTS was oxidized to green ABTS + under the action of appropriate oxidants, and the production of ABTS + could be inhibited in the presence of antioxidants